GOSS · Gossamer Bio, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company's existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 27, 2026TL;DR. Gossamer announced a clear regulatory path for its planned September 2026 NDA submission for seralutinib in PAH after FDA characterized efficacy concerns as review issues rather than filing issues, reacquired worldwide rights from Chiesi in exchange for a capped royalty and milestones, and completed a convertible note exchange that reduced debt by approximately $115.9 million, leaving approximately $57 million in cash as of June 30, 2026.
- + FDA Pre-NDA feedback frames PROSERA efficacy concerns as review issues rather than filing issues, clearing a path to September 2026 NDA submission and potential Q3 2027 approval decision.
- + Gossamer reacquired worldwide rights to seralutinib from Chiesi with no upfront cash payment and received a $5 million payment from Chiesi, retaining the substantial majority of global economics.
- + Convertible note exchange reduced aggregate debt principal by approximately $115.9 million and lowered outstanding 2027 Notes to approximately $18.9 million.
- − FDA has not yet accepted the planned NDA for filing or completed substantive review, and approvability remains uncertain.
- − Company had only approximately $57 million in cash as of June 30, 2026, which may be insufficient to fund a full commercial launch without additional capital.
- − Future performance is entirely dependent on the success of seralutinib, creating concentration risk.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, Cash Equivalents and Marketable Securities | $57M | second quarter ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GOSS
this stock
Gossamer Bio, Inc.
|
$66.85M | — | -57.7% | — | 15.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GOSS | -2.1% | -23.9% | -66.6% | -9.6% | -95.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -1.9% | -23.5% | -78.8% | -10.5% | -108.5% |